Details
Category: Volume 06 Issue 07 July 2018
Hits: 1028

Title: Role of Serum Paraoxonase 1 (PON1) as a Marker of Coronary Heart Disease in Post-Menopausal Women secondary to reduction in serum HDL-C

Authors: Dr Shyam Khanderao Kulkarni, Dr Sanjay Shukla, Dr Rahul Kunkulol, Dr Sayyed Asif Umar

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i7.145

Abstract

Background: In postmenopausal women, partly in relation to advancing age and partly due to estrogen deficiency, there is increased risk of coronary heart disease (CHD). The oxidation of Low density lipoprotein (LDL) is centrally involved in the initiation of atherosclerosis which ultimately results in CHD. Paraoxonase 1 (PON1) is a major antiatherosclerotic component of High density lipoprotein (HDL) which retards the oxidation of LDL.  This study aimed to evaluate the relation between Paraoxonase1 (PON1) activity and post-menopausal status

Methods: On the basis of consecutive recruitment, 80 women between 20 and 76 years old participated in the study. Anthropometric indices (waist circumference, Body mass index) and biochemical parameters (fasting blood glucose, Total cholesterol, Triglyceride, HDL cholesterol and PON1) were measured.

Results: Post-menopausal women in comparison to pre-menopausal women, have significantly low HDL cholesterol and PON1 activity and significantly increased Triglyceride and VLDL cholesterol. PON1 activity was negatively correlated with age, TC, TG, LDL-C. (r = -0.574, -0.119, -0.226, -0.473 respectively) and positively correlated with HDL-C (r = 0.368). Stepwise multiple regression analysis demonstrated HDL-C and menopausal status as the best determinant for PON1 (R2 5 0.320, p < 0.05)

Conclusion: The use of PON1 measurement may facilitate a simple parameter to evaluate the risk of CHD and to work on its secondary prevention.

References

  1. Park’s Textbook of PSM, 20th edition, K Park, Atherosclerosis, noncommunicable diseases, page 316-317. Bhanot publication.
  2. Sybil L Crawford, C B Johannes. The epidemiology of cardiovascular diseases in postmenopausal women. Clin. Endocrinol. Metab.1999;84: 1803-18066)

Tremollieres F A, Pouilles J M, cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis, 1999; 142: 415- 423.

  1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult Treatment Panel III) Final Report. Circulation 2002;106:3153.
  2. Gaspard UJ, Gottal JM, van den Brûle F a. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas. 1995;21(95):171–8.
  3. Goh VHH, Tong TYY, Mok HPP, Said B. Differential impact of aging and gender on lipid and lipoprotein profiles in a cohort of healthy Chinese Singaporeans. Asian J Androl. 2007;9(6):787–94.
  4. Tremollieres F A, Pouilles J M, cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis, 1999; 142: 415- 423.
  5. Selby J V, Austin M A,Newman B, Zhang D et al. LDL subclassphenotype and the insulin resistance syndrome in women.Circulation 1993; 88: 381-387.
  6. J George fodor, rayka Tzerovska. Coronary heart disease: is gender important? The J of men health and gender; 2004;1(1):32-37
  7. Yen Y Tan, et al , gender differences in risk factors for coronary heart disease. Maturitas 2010;65:149-160
  8. Yichuan Wen et al, Effect of menopause on low density lipoprotein oxidation:is estrogen an important determinant?Maturitas 2000;34:233-8
  9. Valeria zago, Silvia S. Brites F. Berg G et al. Impaired HDL antioxidant activity in healthy postmenopausal women. Atherosclerosis, 2004; 177: 203-210.
  10. Watson a D, Berliner J a, Hama SY, La Du BN, Faull KF, Fogelman a M, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96(December):2882–91.
  11. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33(33):498–507.
  12. Tward a. Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice. Circulation [Internet]. 2002;106:484–90. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.0000023623.87083.4F
  13. Adkins S, Gan KN, Modyt M, Dut BN La. Molecular Basis for the Polymorphic Forms of Human Serum Paraoxonase/Arylesterase: Glutamine or Arginine at Position 19 1, for the Respective A or B Allozymes. Am J Hum Genet. 1993;52:598–608.
  14. Mackness M, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl [Internet]. 2002;3:49–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15313350
  15. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35:214–27.
  16. De Aloysio D, Gambacciani M, Meschia M, Pansini F, Modena AB, Bolis PF, et al. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis. 1999;147:147–53.
  17. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res [Internet]. 1994; 35:779–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8071601
  18. Michal Harel, Amir Aharoni, Leonid Gaidukov, Boris Brumshtein, OlgaKhersonsky, Ran Meged et al. Structure and evolution of the serumpara-oxonase family of detoxifying and anti- atherosclerotic enzymes.Nature structural and molecular biology. 2004;11: 412-419
  19. Kumru S, Aydin S, Aras A, Gursu M, Gulcu F. Effects of surgicalmenopause and oestrogen replacement therapy on serumparaoxonase activity and plasma malondialdehyde concentration.
  20. Seres I, Paragh G, Deschene E, Fulop T, Khalil A. Study of factorsinfluencing the decreased HDL associated PON1 activity with aging.Experimental Gerontology 2004; 39: 59-66.
  21. Topcuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G. etal. The effect of hormone replacement therapy on oxidized low densitylipoproteinlevels and paraoxonase activity in postmenopausalwomen. Tohoku J. Exp. Med. 2005; 205:79-86.
  22. Matthias Barton, Mark M Kockx. Estrogen and apoptosis inatherosclerosis. International Congress series, 2002; 1229: 81-93
  23. Michael I Mackness and Colin H Walker. Multiple forms of sheepserum Aesterase activity associated with the high density lipoprotein.Biochem J. 1988; 250: 539-545.
  24. Aviram M, Scott B, Robert S, Charles B, Roger N, Rosenblat M.Paraoxonase active site required for protection against LDL oxidationinvolves free sulfhydryl group and is different from that required for itsarylesterase/paraoxonase activities : selective action of humanparaoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol1998;18;1617-1624.
  25. Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio F, et al. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis. 2004;177:203–10
  26. Hiroshi Yoshida, Reiko Kisugi. Mechanism of LDL oxidation. Clinica Chimica acta, 2010; 411: 1875-1882
  27. Cagnacci a, Palma F, Romani C, Xholli a, Bellafronte M, Di Carlo C. Are climacteric complaints associated with risk factors of cardiovascular disease in peri-menopausal women? Gynecol Endocrinol [Internet]. Informa UK Ltd; 2015;31(00):359–62.

Corresponding Author

Dr Sanjay Shukla